These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. Stainton SM; Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420477 [TBL] [Abstract][Full Text] [Related]
26. Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa. Gupta A; Landman D; Quale J J Antimicrob Chemother; 2022 Apr; 77(5):1282-1285. PubMed ID: 35134942 [TBL] [Abstract][Full Text] [Related]
27. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. Ito A; Kohira N; Bouchillon SK; West J; Rittenhouse S; Sader HS; Rhomberg PR; Jones RN; Yoshizawa H; Nakamura R; Tsuji M; Yamano Y J Antimicrob Chemother; 2016 Mar; 71(3):670-7. PubMed ID: 26645269 [TBL] [Abstract][Full Text] [Related]
29. Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae. Lan P; Lu Y; Jiang Y; Wu X; Yu Y; Zhou J Int J Antimicrob Agents; 2022 Oct; 60(4):106646. PubMed ID: 35918032 [TBL] [Abstract][Full Text] [Related]
30. Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic. Streling AP; Al Obaidi MM; Lainhart WD; Zangeneh T; Khan A; Dinh AQ; Hanson B; Arias CA; Miller WR Clin Infect Dis; 2021 Dec; 73(11):e4472-e4474. PubMed ID: 33411899 [TBL] [Abstract][Full Text] [Related]
31. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report. Stevens RW; Clancy M Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054 [TBL] [Abstract][Full Text] [Related]
32. Treatment of carbapenem-resistant Canton R; Doi Y; Simner PJ Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1077-1094. PubMed ID: 35502603 [TBL] [Abstract][Full Text] [Related]
33. Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data? Shields RK Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015037 [TBL] [Abstract][Full Text] [Related]
34. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse? Simner PJ; Patel R J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829 [TBL] [Abstract][Full Text] [Related]
35. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925 [TBL] [Abstract][Full Text] [Related]
36. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Katsube T; Miyazaki S; Narukawa Y; Hernandez-Illas M; Wajima T Eur J Clin Pharmacol; 2018 Jul; 74(7):931-938. PubMed ID: 29627897 [TBL] [Abstract][Full Text] [Related]